This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment

Volume: 105, Issue: 6, Pages: NP28 - NP31
Published: Feb 19, 2019
Abstract
Purpose: Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when and which TKI has to be started in R/M MTC patients. This is due to 1) TKI-related toxicity burden, 2) no overall survival benefit for either TKI, and 3) progression-free survival improvement in MTC subgroups ( RETM918T and RAS mutations) treated with...
Paper Details
Title
The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment
Published Date
Feb 19, 2019
Volume
105
Issue
6
Pages
NP28 - NP31
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.